Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Bioardis LLC currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, which introduces different perspectives into the prosecution process compared to a single-examiner approach. Despite having multiple examiners, the portfolio is concentrated within 1 distinct art unit, suggesting that the applications are technically similar enough to be grouped together by the USPTO. This focus on 1 distinct art unit provides a consistent administrative backdrop for the company's filings.
The busiest examiner for the portfolio is DAHLE, CHUN WU, who is responsible for 1 busiest examiner pending office action. This indicates that the 2 pending office actions are divided among the examiners. This arrangement means the company must navigate the specific requirements of the 2 distinct examiners while operating within the administrative framework of 1 distinct art unit. The presence of the 2 pending office actions shows the current level of active engagement with the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258203 | FAP BINDING MOLECULES AND USES THEREOF | HADDAD, MAHER M | — |
| 18268215 | MESOTHELIN BINDING MOLECULES AND USES THEREOF | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258203 | FAP BINDING MOLECULES AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18268215 | MESOTHELIN BINDING MOLECULES AND USES THEREOF | DAHLE, CHUN WU | 1641 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial